Compare Genuine Parts Company (GPC) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs McKesson Corporation — how do they compare? Genuine Parts Company trades at $125.11 (market cap $16.65B), while McKesson Corporation trades at $821.18 (market cap $93.23B). The key difference: McKesson Corporation is far larger — about 5.6× Genuine Parts Company's market cap, and Genuine Parts Company pays the higher dividend (3.51%). Which is the better fit depends on your goals.
| GPC | MCK | |
|---|---|---|
Market Cap | $16.65B | $93.23B |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $995.69 |
52-Week Low | $92.47 | $659.01 |
Enterprise Value | $22.87B | $97.87B |
Dividend Yield | 3.51% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Genuine Parts Company (GPC) trades at $122.16, down 1.1% on the day, with a bullish technical signal supported by moving averages and oscillators. Fundamentally, the company shows strong revenue growth to $24.3B in 2025 but faces significant margin compression, with net income plummeting to $66M (0.27% margin) from $904M the prior year. The stock carries a high P/E of 275 but reasonable P/S of 0.68, while analysts maintain a consensus 'Buy' rating with a $133 price target. Recent news highlights GPC's upcoming Q2 2026 earnings report on July 21, 2026, and its status as a Dividend King with 70 consecutive years of dividend increases.
The outlook presents a mixed picture: technical strength and dividend reliability support the stock, while deteriorating profitability and high valuation multiples pose significant risks. Investment opportunity lies in potential earnings recovery and continued dividend growth, but investors face headwinds from margin pressure and elevated P/E ratio requiring careful monitoring of upcoming quarterly results.
McKesson (MCK) trades at $803.37, down 1.1% on the day, with technical indicators showing a neutral to bullish bias as the price sits near pivot point $805. The company demonstrates strong fundamental momentum with revenue growing from $264B in 2022 to $359.1B in 2025, and a consistent track record of beating earnings estimates in recent quarters. Analyst sentiment is overwhelmingly positive, with 80% recommending Buy and a consensus price target of $932.83, representing a 16% upside from current levels.
The outlook for MCK is favorable, supported by robust revenue growth, expanding profitability, and strong analyst conviction. Key opportunities include continued execution in specialty pharma and oncology services. Primary risks involve policy changes affecting healthcare distribution, intense industry competition, and execution challenges in integrating growth initiatives, which could pressure margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
